Advertisement

Topics

Novartis’ Zykadia smashes Phase III target for lung cancer

04:12 EDT 23 Sep 2016 | Pharmafile

Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating its efficacy in treating patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer.

Zykadia, an orally-administered selective inhibitor of anaplastic lymphoma kinase, showed a significant improvement in progression-free survival in previously untreated patients compared to standard chemotherapy.

read more

Original Article: Novartis’ Zykadia smashes Phase III target for lung cancer

NEXT ARTICLE

More From BioPortfolio on "Novartis’ Zykadia smashes Phase III target for lung cancer"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...